Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types
about
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionDiabetes and cancer: two diseases with obesity as a common risk factorChemotherapy and chemoprevention by thiazolidinedionesPax-8-PPAR-γ fusion protein in thyroid carcinomaAnticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.T0070907, a PPAR γ inhibitor, induced G2/M arrest enhances the effect of radiation in human cervical cancer cells through mitotic catastrophe.Alternative activation-skewed microglia/macrophages promote hematoma resolution in experimental intracerebral hemorrhage.Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.Nitrostyrene Derivatives Act as RXRα Ligands to Inhibit TNFα Activation of NF-κB.Pharmacological repression of PPARγ promotes osteogenesisMiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cellsMetabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer CellsDown-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells.Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosisPPARγ maintains ERBB2-positive breast cancer stem cells.Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis.Synergistic Antiproliferative Effects of Combined γ -Tocotrienol and PPAR γ Antagonist Treatment Are Mediated through PPAR γ -Independent Mechanisms in Breast Cancer Cells.Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.Peroxisome proliferator-activated receptor γ upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer.Release of cyclic phosphatidic acid from gelatin-based hydrogels inhibit colon cancer cell growth and migration.Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes.PPARγ antagonist GW9662 induces functional estrogen receptor in mouse mammary organ culture: potential translational significance.Alpha-Tocopherol prevents esophageal squamous cell carcinoma by modulating PPARγ-Akt signaling pathway at the early stage of carcinogenesis.Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor.Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: A meta-analysis.Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trialsA structural mechanism for directing corepressor-selective inverse agonism of PPARγ
P2860
Q24601222-F8F53A37-4651-4AC3-9B7E-D844C98EC01BQ26822753-C5F9A872-7ABB-4080-908C-6325E609A8F4Q27011352-FFBB050A-5A94-4C5E-A1C0-53A5541F0BBFQ28244806-C62BC91A-7D9D-482C-AC83-11A815AF1430Q33692555-53162FB0-C686-45D6-8D35-222F68BD0AB6Q34417994-CDE04752-C07A-4F27-B86E-DE3D0FF511FEQ34554517-24FF100D-A9FA-48DB-B76A-1ACA01EA11DFQ35417323-0385F03E-38D4-4AD3-A2C2-A0864CE72B03Q35612396-A21C2531-2BA3-4A01-9C2E-DB67430A8064Q35754510-20534E9F-B0AB-4985-B3E9-F47F15160794Q35791401-803B23C0-234D-4554-AF05-20500367E3A1Q36342398-5509C520-0E33-43D6-A09A-220C584091BCQ36602967-91F9208D-1F07-4EB2-AF8A-332F4561F5F7Q37038408-8A51A122-F1E3-4CE0-8165-491D4A3D0A23Q37146010-F9487175-CB3E-4794-90CC-7511A26BB77AQ37501777-B2A468FE-3AF1-4EFF-9E44-EB4C05FC4D6EQ37624375-F44E5EDA-A68C-4CDF-88E2-DC5CB2F035AFQ37651124-A8448D24-4764-4A2A-B1BD-E90F149BA50AQ38651175-FFAC9B7A-E00B-43B2-9F92-F812C0D8CFE6Q38979843-97AD8F0F-3345-4A89-B13B-C4EBAB083759Q39272192-0FFA08C1-49F0-4AF7-9269-2047AEEE2A91Q42965001-3CCD3C85-ED9E-4149-B6D7-3BBA86CEDF0DQ44588198-2504B623-9440-4586-866D-22A8850D9D40Q47097475-DF2C0FA8-E5C6-4D67-B5CC-D41A1D2AC53CQ49433973-14D4AFA5-F299-474D-8894-84DD27DA1C10Q52594525-E212C7D9-E16E-4342-968B-2FCEA2AE27A3Q58393670-857260A0-6FD4-47B4-9CDE-B716FA5EDCEBQ58586525-DDE55BCE-963A-43D7-9167-63EA97C02D96
P2860
Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential of peroxisome prolif ...... r a wide range of cancer types
@en
Potential of peroxisome prolif ...... a wide range of cancer types.
@nl
type
label
Potential of peroxisome prolif ...... r a wide range of cancer types
@en
Potential of peroxisome prolif ...... a wide range of cancer types.
@nl
prefLabel
Potential of peroxisome prolif ...... r a wide range of cancer types
@en
Potential of peroxisome prolif ...... a wide range of cancer types.
@nl
P2093
P2860
P356
P1433
P1476
Potential of peroxisome prolif ...... r a wide range of cancer types
@en
P2093
David M Goldenberg
Jack D Burton
Rosalyn D Blumenthal
P2860
P304
P356
10.1155/2008/494161
P577
2008-01-01T00:00:00Z